These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34751763)

  • 21. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 25. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Fate of FDA Postapproval Studies.
    Woloshin S; Schwartz LM; White B; Moore TJ
    N Engl J Med; 2017 Sep; 377(12):1114-1117. PubMed ID: 28930510
    [No Abstract]   [Full Text] [Related]  

  • 28. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 31. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 32. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 33. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
    Mooghali M; Mohammad A; Wallach JD; Mitchell AP; Ross JS; Ramachandran R
    JAMA Netw Open; 2024 May; 7(5):e249233. PubMed ID: 38691363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-stage drug approval would reduce the risks.
    Frantz JA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
    [No Abstract]   [Full Text] [Related]  

  • 35. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in regulatory science at the Food and Drug Administration.
    Psaty BM; Goodman SN; Breckenridge A
    JAMA; 2013 May; 309(20):2103-4. PubMed ID: 23695478
    [No Abstract]   [Full Text] [Related]  

  • 38. Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms.
    Gyawali B; Ross JS; Kesselheim AS
    JAMA Intern Med; 2021 Oct; 181(10):1275-1276. PubMed ID: 34254981
    [No Abstract]   [Full Text] [Related]  

  • 39. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.